According to Piper Jaffray, Abiomed ABMD price target is raised to $27.
Piper Jaffray said that the Street was looking for a big quarter, and ABMD delivered. “Robust Impella sales were driven by 44% US growth (43% globally) as physician adoption accelerates on the back of recent SCAI guidelines.”
Abiomed closed yesterday at $23.22.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in